9.61
-0.20
(-1.99%)
As of 8:00:43 AM GMT+2. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 15 | 15 |
| Avg. Estimate | 1.06B | 1.12B | 4.63B | 6.58B |
| Low Estimate | 902.4M | 921.79M | 3.66B | 4.69B |
| High Estimate | 1.17B | 1.25B | 5.3B | 8.97B |
| Year Ago Sales | 1.04B | 1.23B | 4.8B | 4.63B |
| Sales Growth (year/est) | 2.75% | -8.81% | -3.52% | 42.08% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| IZ1.F | -- | -- | -- | -- |
| S&P 500 | 6.55% | 6.50% | 9.70% | 14.29% |
Upgrades & Downgrades
| Maintains | Raymond James: Market Perform to Market Perform | 3/20/2024 |
| Maintains | JP Morgan: Neutral to Neutral | 10/12/2023 |
| Maintains | Scotiabank: Outperform | 6/28/2023 |
| Reiterates | Canaccord Genuity: Buy | 6/15/2023 |
| Maintains | JP Morgan: Neutral | 6/30/2015 |
| Maintains | JP Morgan: Neutral | 1/23/2015 |